Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197
-
Upload
travis-gentry -
Category
Documents
-
view
27 -
download
2
description
Transcript of Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197
Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197
Baseline characteristics of study population of new users and non-users of statins
Values are numbers (percentages) unless stated otherwise
Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197
Crude incidence per 10 000 person years for study outcomes in both men and women
Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197
Risk associated with statin type both in men and in women for non-significant and marginal outcomes
Hip
pisl
ey-C
ox J
, C
oupl
and
C.
B
MJ
2010
;340
:c21
97
Risk of significant outcomes associated with type and dose of statin both in men and in women - Part I
Hip
pisl
ey-C
ox J
, C
oupl
and
C.
B
MJ
2010
;340
:c21
97
Risk of significant outcomes associated with type and dose of statin both in men and in women - Part II
Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197
Relative incidence rate ratios from case series analysis for men and women combined for
significant outcomes associated with statin type
Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197
Numbers needed to harm (NNH) or numbers needed to treat (NNT) and numbers of extra or prevented cases for each outcome over five years in patients aged 35-74
free of cardiovascular disease at baseline with QRISK2 score of ≥20% or ≥15%
Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197